The Healthcare sector in India grew strongly in Q2 of FY25, with revenue increasing by 17.6 per cent year on year (YoY), according to a report.
The
report by Axis Securities showed that the healthcare sector also grew strongly
by 10.4 per cent in quarter on quarter (QoQ).
Hospital
occupancy rates, which rose by 340 basis points (bps) YoY and 470 bps QoQ were
a key driver behind the growth.
Further,
insurance payers contributed 33 per cent of total revenues in the hospital
segment -- marking a 23 per cent YoY and 12 per cent QoQ growth.
However,
the insurance penetration continues to remain low, the report said. It also
offers room for expansion as awareness and purchasing power increase.
The
report noted that cancer and cardiac care continue to drive double-digit
growth. This, in addition to rising occupancy rates and Average Revenue Per
Occupied Bed (ARPOB), is expected to sustain future growth in the healthcare
sector, it added.
The
report also recorded strong growth in the Indian pharma sector in Q2 FY25.
Major
pharmaceutical companies in India reported a 10 per cent YoY growth in Q2 of
FY25. This has been driven by impressive performance in North America and the
domestic market.
The
Indian Pharmaceutical Market (IPM) grew by 8 per cent YoY, with chronic
therapies seeing a 9 per cent increase. However, acute therapies experienced a
modest 4 per cent growth due to a weaker season.
The
report highlighted that the pharmaceutical sector under coverage recorded a
10.2 per cent YoY and 1.7 per cent QoQ growth, led by a 10.8 per cent YoY
increase in North America and a 9.8 per cent YoY rise in the Indian business.
The
outlook for the pharmaceutical sector remains positive over the next three
years, with a promising pipeline in biosimilars, GLP-1 (glucagon-like
peptide-1), and peptides, all of which are important in treating diabetes and
other conditions.
Companies
with a significant share of chronic therapy portfolios continue to outperform
the broader market.
No comments:
Post a Comment